期刊文献+

北京市丰台区某接种点国产轮状病毒口服活疫苗的使用状况分析 被引量:5

The utilization status of Lanzhou lamb rotavirus vaccine among children at a vaccination center in Fengtai district Beijing
原文传递
导出
摘要 目的了解我国国产轮状病毒口服活疫苗的接种比例及实际接种程序,对该疫苗使用的接种程序提出修改意见。方法对北京丰台某接种点登记在册的2007年1月1日至2010年12月31日出生的儿童轮状病毒口服活疫苗接种情况进行分析,包括接种比例,接种年龄,接种季节。结果轮状病毒疫苗的接种比例为39.7%,81.6%的儿童接种1剂,接种2、3剂次的比例为15.8%及2.6%,79.7%的儿童在18月龄之前进行首剂接种,首剂接种高峰年龄为10月龄,20月龄出现接种小高峰。首剂与第二剂次的接种间隔为12个月。接种有季节性,高峰接种季节为7—9月。结论目前的免疫程序不合理,结合我国轮状病毒流行特点及我国其他疫苗使用程序,推荐三种接种程序,2~4月龄接种,5—7月龄接种,9—11月龄接种。 Objective To understand the vaccine coverage and the immunization schedule of Lanzhou Lamb Rotavirus vaccine and to develop a reasonable immunization schedule. Methods To analyze the vaccine coverage, age of immunization and vaccination season of a birth cohort from January 1 2007 to December 31't 2010 who registered in one vaccination center in Fengtai District Beijing. Results The vaccine coverage was 39.7% in total, among which children immunized for 1 dose, 2 doses and 3 doses accounted for 81.6% , 15.8% and 2. 6% , respectively. There were 79. 7% children who took their first dose by the age of 18 months. 10 months of age is the peak immunization age. The intervals between the first and the second dose was 12 months. The peak season of administration was from July to September. Conclusion The current recommended immunization schedule is not proper according to the rotavirus epidemiology in China. Lanzhou Lamb Rotavirus vaccine is recommended to be administered b at 2-4, 5-7 or 9-11 months of age.
出处 《中华实验和临床病毒学杂志》 CAS CSCD 2012年第3期199-201,共3页 Chinese Journal of Experimental and Clinical Virology
关键词 轮状病毒疫苗 接种 免疫接种程序表 Rotavirus vaccines Vaccination immunization schedule
  • 相关文献

参考文献8

  • 1Murphy TV,Gargiullo PM,Massoudi MS. Intussusception among infants given an oral rotavirus vaccine[J].New England Journal of Medicine,2001.564-572.doi:10.1056/NEJM200102223440804.
  • 2Ruiz-Palacios GM,Perez-Schael I,Velazquez FR. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis[J].New England Journal of Medicine,2006.11-22.doi:10.1056/NEJMoa052434.
  • 3Vesikari T,Matson DO,Dennehy P. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine[J].New England Journal of Medicine,2006.23-33.doi:10.1056/NEJMoa052664.
  • 4Yesikari T,Karvonen A,Forrest BD. Neonatal administration of rhesus rotavirus tetravalent vaccine[J].Pediatric Infectious Disease Journal,2006.118-122.
  • 5Gladstone BP,Ramani S,Mukhopadhya I. Protective effect of natural rotavirus infection in an Indian birth cohort[J].New England Journal of Medicine,2011.337-346.
  • 6Duan ZJ,Liu N,Yang SH. Hospital-Based Surveillance of Rotavirus Diarrhea in the People's Republic of China,August 2003-July 2007[J].Journal of Infectious Diseases,2009,(Suppl 1):S167-S173.
  • 7Zaman K,Sack DA,Yunus M. Successful coadministration of a human rotavirus and oral poliovirus vaccines in Bangladeshi infants in a 2-dose schedule at 12 and 16 weeks of age[J].Vaccine,2009,(9):1333-1339.doi:10.1016/j.vaccine.2008.12.059.
  • 8Pltkin S,Orenstein W,Offit P. Vaccines[A].Elsevier Inc,2008.

同被引文献46

引证文献5

二级引证文献38

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部